Viyash Scientific Ltd Board of Directors
Board of Directors at Viyash Scientific Ltd
Non-Exec & Non-Independent Dir
Non-Exec & Non-Independent Dir
Non Executive Director
Chairman & Independent Directo
Non-Exec. & Independent Dir.
Key Highlights
- Gregory John Andrews continues to serve as the Non-Executive & Non-Independent Director in 2025, maintaining the same position as in the previous year.
- Fabian Kausche continues to serve as the Non-Executive & Non-Independent Director in 2025, maintaining the same position as in the previous year.
- Kamal K Sharma joins the board as Chairman & Independent Director, in a new position in 2025. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Milind Sarwate joins the board as Non Executive & Independent Director, in a new position in 2025. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- N Rajaram joins the board as Whole Time Director & Chief Executive Officer, in a new position in 2025. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
Viyash Scientific Ltd
NSE: VIYASH
Share Price
Last Ten Days Market Price
| Date | |
|---|---|
| 15 May 2026 | 224.45 |
| 14 May 2026 | 230.65 |
| 13 May 2026 | 224.55 |
| 12 May 2026 | 214.9 |
| 11 May 2026 | 225.3 |
| 08 May 2026 | 219 |
| 07 May 2026 | 221.8 |
| 06 May 2026 | 219.65 |
| 05 May 2026 | 200.75 |
| 04 May 2026 | 204.65 |
Company Fundamentals for Viyash Scientific Ltd
Market Cap
9,805 Cr
EPS
3.0
P/E Ratio (TTM)
75.1
P/B Ratio (TTM)
11.6
Day’s High
230.9
Day’s Low
223.65
DTE
0.6
ROE
15.2
52 Week High
260.3
52 Week Low
166.2
ROCE
18.2
Market Price of Viyash Scientific Ltd
1M
1Y
3Y
5Y
Viyash Scientific Ltd News Hub
Sequent Scientific receives WHO prequalification approval for Albendazole API
Sequent Scientific announced its receipt of prequalification (PQ) approval from the World Health Org
Read more
20 Aug 24
Sequent Scientific hits 52-week high after receiving prequalification approval for Albendazole
This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialise
Read more
20 Aug 24
Sequent Scientific reports consolidated net profit of Rs 6.51 crore in the June 2024 quarter
Net profit of Sequent Scientific reported to Rs 6.51 crore in the quarter ended June 2024 as against
Read more
16 Aug 24
Sequent Scientific to table results
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 14 August 2024. P
Read more
09 Aug 24
